Skip to main content

Table 3 Anterior pituitary function at presentation and during follow-up

From: Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis

No. At presentation Follow-up
  AP deficiency GH (ng/mL, <2.5) IGF1 (ng/mL, 74–388) ACTH (pg/mL, 0–46) Cortisol (μg/dL, 4–25) LH (IU/L, 1.2–58.64) FSH (IU/L, 1.27–113.59) PRL (ng/mL, 2.74–26.72) E2 (pg/mL, 20–273) T (ng/dL, 0.1–7.8) TSH (μIU/mL,0.38–4.34) FT4 (ng/dL,0.81–1.89) AP deficiency
1 Panhypopituitary 0.2 25 15.29 0.81 0 0.2 15.84 10.4 11.2 0.202 0.56 Panhypopituitary
2 Not impaired 0.5 129 28. 6 13.51 3.12 4.91 37.1 44 0.19 1.54 1.22 Not impaired
3 GH, LH-FSH deficiency <0.05 72 26.3 12.05 0.43 0.36 17.39 25 <0.1 8.485 1.01 Panhypopituitary
4 Not impaired 1.4 198 30.6 12.9 2.63 1.0 15.6 11.8 360.8 2.662 1.380 NA
5 Panhypopituitary <0.05 44 7.6 0.74 0 0.3 11.7 10.2 5.2 2.539 0.60 Panhypopituitary
6 Not impaired 0.2 381 51.3 13.65 4.7 4.42 18.14 56 2.11 2.581 1.333 Not impaired
7 Panhypopituitary 0.12 68 7.6 0.2 5.2 1.67 51.22 0.09 0.73 0.26 0.77 Panhypopituitary
  1. AP anterior pituitary, GH growth hormone, IGF1 insulin-like growth factor-1, ACTH adrenocorticotropic hormone, LH luteinizing hormone, FSH follicle-stimulating hormone, PRL prolactin, E2 oestradiol, T testosterone, TSH thyroid-stimulating hormone, FT4 free thyroxine